Although it has been described that an enhanced NRF2 axis may support abnormal angiogenesis, increased permeability, and survival of aberrant endothelial/vascular cells, moderate NRF2 activation could drive a cytoprotective program against brain tumors or cancer cells by downregulating TIE2/Tek expression, thereby preventing the angiogenesis process and metastasis. This evidence concerns the gene NFE2L2 and cancer.